P/B
—
Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
$135.4M
Market Cap • 11/6/2026
1999
(27 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
France
Country
Valuation
P/S
12
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
135,4M
EV
146,1M
EV/Revenue
12,9
EV/EBITDA
-2,7
EV/EBIT
-2,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-519,5M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
409,3%
Capex/Revenue
1,8%
Capex/D&A
13,3%
Capex/OCF
-0,3%
SBC/OCF
—
% PPE
10,5%
% Goodwill
0%
ROE
273,5%
ROIC
—
Growth
CAGR EPS 5Y
-13,2%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,6
Quick Ratio
0,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!